GHK-Cu (Copper Peptide) Deep Dive: Mechanisms, Benefits, Risks, Forms, & Dosing
Quinn Stillson, a physician, walks through what is known about GHK-Cu: its proposed mechanisms, the limited human data, his safety views, topical versus injectable forms, and his dosing preferences.
Key moments
Tap a moment to play the video from there.
- 0:41Structure and gene-regulating mechanismStillson explains that GHK binds copper readily and says its main action is regulating gene expression, not just carrying copper into tissues.
- 2:19Skin regeneration and the human dataHe describes how he thinks GHK-Cu acts on collagen, stem cells and blood vessels in skin, then lists the human skin and wound studies he knows of.
- 8:08Hair growth evidenceStillson covers preclinical comparisons with minoxidil and one transplant-related result he says is only partly documented publicly.
- 12:03Lung, gut, liver and musculoskeletal dataHe reviews preclinical work across several tissues and says he prefers other peptides for musculoskeletal injuries.
- 18:27Cancer pathways, heart and brainStillson describes proposed mechanisms in each area and stresses that interventional evidence is very limited.
- 28:00Copper toxicity and lab monitoringHe argues copper exposure from a typical dose is small and lists the labs he would want before and during use.
- 33:51Who he thinks might use itStillson sorts use cases into skin and hair, musculoskeletal repair, longevity and other tissue work, saying where he ranks it for each.
- 37:27Making topical forms workHe covers absorption problems, liposomal and other formulations, pH, compounding pharmacies, microneedling and hyaluronic acid pre-treatment.
- 46:36Dosing, frequency and cyclesStillson gives his reasoning for topical concentrations, subcutaneous starting doses, daily use and on and off cycles.
What the video says
Quinn Stillson, who describes himself as a licensed physician certified in peptide therapy, gives a long educational overview of GHK-Cu, a three amino acid peptide with a strong affinity for copper. He says its main mechanism is regulating gene expression, not the copper transport that was first assumed, and cites a figure of 32% of human genes. He organizes the talk around seven effects he describes: skin, hair, inflammation and oxidation, other tissue repair, cancer pathways, cardiovascular, and neurologic and longevity effects.
Stillson is open about how thin the evidence is outside the skin. He says skin is where most human data exists, citing a study where 70% of people using a topical form had improved collagen synthesis, placebo-controlled trials in middle-aged women over 3 months, and a gel used on diabetic foot ulcers. He adds that many of these studies lack public methodology. For hair, lungs, gut, muscle, brain and longevity, he says the support is mainly mechanistic or from preclinical studies, and that he knows of no human interventional studies for most of them.
On safety, Stillson says he has low concern about copper toxicity because a 2 mg dose supplies far less copper than the diet already does. He still likes baseline and ongoing labs, including serum copper, ceruloplasmin, liver enzymes and iron markers. He advises against use during active cancer, citing its angiogenic properties and the lack of human data on the injectable form. He also notes that the injectable form is not FDA approved for human use and that stinging at the injection site is a common complaint.
The last third is practical. Stillson prefers a well-made topical product, ideally from a compounding pharmacy, with microneedling and hyaluronic acid, over injections for skin and hair. He says injections make more sense for systemic goals. He calls his dosing views speculative: topical starting at 0.5% to 2%, and subcutaneous starting at 0.5 mg per day, moving up toward 1 to 2 mg, with cycles of 3 to 4 weeks on and 1 to 2 weeks off.
On each compound
GHK-Cu0:41
Stillson says GHK-Cu works mainly by regulating gene expression and calls it one of the most versatile peptides in theory. He says human evidence is mostly topical and skin-related, and that injectable human data is absent.
See how your DNA reads GHK-CuBPC-15718:27
Stillson says there is much more data for BPC-157 than for GHK-Cu in musculoskeletal repair, and that he would favor BPC-157 for moderate to severe injuries in people with low cancer risk. He says he is more cautious about BPC-157 than GHK-Cu in people with higher cancer risk.
See how your DNA reads BPC-157What this video doesn’t settle
- Stillson says no human studies exist for injectable GHK-Cu, so the injectable dosing and safety views in the video are reasoned from preclinical data and mechanisms.
- Many of the human skin and hair results he cites come from studies without public methodology, so the figures cannot be checked from the video.
- The anti-inflammatory, cancer-pathway, cardiovascular, neurologic and longevity effects are presented as mechanistic or preclinical, and he says some, such as longevity, have no interventional studies in any species.
Questions this video answers
What does Quinn Stillson say about GHK-Cu and copper toxicity?
Stillson says he has very low concern, because a 2 mg injected dose supplies roughly 20 to 30% of the copper already in a typical diet. He still prefers labs such as serum copper, ceruloplasmin, liver enzymes and iron markers before and during use, and says Wilson's disease would be a reason to avoid it.
Is topical or injectable GHK-Cu better for skin and hair?
Stillson says he prefers a high-quality, well-applied topical for skin and hair, because he expects an injected dose to be diluted across the body. He says injection is the route to consider for systemic goals like longevity, since topical use will not reach systemic levels.
What GHK-Cu doses does Stillson suggest?
For topical use he suggests starting at the low end of 0.5% to 2%, applied once daily. For subcutaneous use he likes starting at 0.5 mg per day, moving up in 0.5 mg steps to as much as 2 mg, and says he often lands near 1 mg per day for general longevity. He describes this as speculative because there are no human injectable studies.
How does Stillson suggest reducing GHK-Cu injection site burning?
He says the stinging is most likely from the copper component. He suggests diluting the dose into more volume, injecting more slowly, and splitting the dose across sites with fresh needles.
How long does Stillson suggest cycling GHK-Cu?
For general anti-aging use with the injectable form, he suggests a starting point of 3 to 4 weeks on and 1 to 2 weeks off, to be set with a doctor. He says topical use could continue indefinitely if skin irritation is monitored.
Video by Quinn Stillson MD on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
